The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: An exploratory study

Therapeutic Advances in Respiratory Disease

Volumn 3, Issue 2, 2009, Pages 73-80

  Man, S f Paul ^a   Zhang, Xuekui ^a   Vessey, Rupert ^b   Walker, Terry ^b   Lee, Kwan ^b   Park, Dan ^b   Sin, Don D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Biomarker; COPD; corticosteroids; fluticasone; prednisone

Indexed keywords

ADIPONECTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHEMOKINE; EOTAXIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FLUTICASONE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR GAMMA; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; PLACEBO; PREDNISONE; PROLACTIN; PULMONARY AND ACTIVATION REGULATED CHEMOKINE; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DRUG EFFICACY; EXPLORATORY RESEARCH; FEMALE; HUMAN; INFLAMMATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AGED; ANDROSTADIENES; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 67449141057     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465809336697     Document Type: Article

References (22)

1. Barnes, N.C., Qiu, Y.S., Pavord, I.D., Parker, D., Davis, P.A., Zhu, J. et al. (2006). Anti inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173: 736-743.
2. Barnes, P.J., Shapiro, S.D. and Pauwels, R.A. (2003). Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22: 672-688.
3. Bender, R. and Lange, S. (2001). Adjusting for multiple testing - when and how? J Clin Epidemiol 54: 343-349.
4. Blankenberg, S., Barbaux, S. and Tiret, L. (2003). Adhesion molecules and atherosclerosis. Atherosclerosis 170: 191-203.
5. Burge, P.S., Calverley, P.M., Jones, P.W., Spencer, S., Anderson, J.A. and Maslen, T.K. (2000). Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320: 1297-1303.
6. Gan, W.Q., Man, S.F., Senthilselvan, A. and Sin, D.D. (2004). Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59: 574-580.
7. Huiart, L., Ernst, P., Ranouil, X. and Suissa, S. (2005). Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 25: 634-639.
8. Jemal, A., Ward, E., Hao, Y. and Thun, M. (2005). Trends in the leading causes of death in the United States, 1970-2002. J Am Med Assoc 294: 1255-1259.
9. Kadioglu, A. and Sheldon, P. (1998). Steroid pulse therapy for rheumatoid arthritis: effect on lymphocyte subsets and mononuclear cell adhesion. Br J Rheumatol 37: 282-286.
10. Keh, D., Boehnke, T., Weber-Cartens, S., Schulz, C., Ahlers, O., Bercker, S. et al. (2003). Immunologic and hemodynamic effects of ‘low-dose’ hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167: 512-520.
11. Lofdahl, C.G., Postma, D.S., Pride, N.B., Boe, J. and Thoren, A. (2007). Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J 29: 1115-1119.
12. Macie, C., Wooldrage, K., Manfreda, J. and Anthonisen, N.R. (2006). Inhaled corticosteroids and mortality in COPD. Chest 130: 640-646.
13. Ohta, K. and Yamashita, N. (1999). Apoptosis of eosinophils and lymphocytes in allergic inflammation. J Allergy Clin Immunol 104: 14-21.
14. Pai, J.K., Pischon, T., Ma, J., Manson, J.E., Hankinson, S.E., Joshipura, K. et al. (2004). Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610.
15. Parimon, T., Chien, J.W., Bryson, C.L., McDonell, M.B., Udris, E.M. and Au, D.H. (2007). Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 712-719.
16. Pauwels, R.A. and Rabe, K.F. (2004). Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364: 613-620.
17. Pinto-Plata, V., Toso, J., Lee, K., Park, D., Bilello, J., Mullerova, H. et al. (2007). Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 62: 595-601.
18. Schuld, A., Kraus, T., Haack, M., Hinze-Selch, D., Zobel, A.W., Holsboer, F. et al. (2001). Effects of dexamethasone on cytokine plasma levels and white blood cell counts in depressed patients. Psychoneuroendocrinology 26: 65-76.
19. Shai, I., Schulze, M.B., Manson, J.E., Rexrode, K.M., Stampfer, M.J., Mantzoros, C. et al. (2005). A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care 28: 1376-1382.
20. Sin, D.D., Lacy, P., York, E. and Man, S.F. (2004). Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 760-765.
21. Sin, D.D. and Man, S.F. (2003). Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107: 1514-1519.
22. Stoeck, M., Schafer, M., Hofmann, H.P. and Gekeler, V. (2000). Dexamethasone and cyclosporin A do not inhibit interleukin-15 expression in the human lung carcinoma cell line A549. Eur Cytokine Netw 11: 414-419.